ChemoCentryx Культура компании

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-based therapeutics widely regarded as a Leader in chemokine research, his laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. From December 1993 to November 1996, he worked at the DNAX ResearchInstitute, a division of Schering-Plough Corporation, a pharmaceuticalcompany. Prior to DNAX, Dr. Schall served for seven years as a Scientist of Genentech Inc. With more than 16 years of industry experience, he has published approximately 100 articles in noted peer-reviewed journals, including Cell, Nature, Science and the Journal of Immunology. Dr. Schall has been the Chairman of the Board of ChemoCentryx, Inc. since April 2012. He has been a Director of ChemoCentryx Inc. since November 1996. He received his B.S. in biology from Northern IllinoisUniversity. Dr. Schall received his Ph.D. in Cancer Biology from Stanford University.

Dr. Markus J. Cappel, PhD has been the Chief Business Officer of ChemoCentryx, Inc. since February 2007 and has been its Treasurer since August 2004. Dr. Cappel served as Senior Vice President of Corporate & Business Development of ChemoCentryx Inc. from March 2003 to February 2007 and Vice President of Business Development from October 2001 to March 2003. He served as Vice President of Business Development at Alkermes Inc., where he was responsible for the Alkermes's AIR pulmonary drug delivery platform. While there, Dr. Cappel contributed to forging two major alliances with Eli Lilly, a multi-product deal with GlaxoSmithKline and an exclusive development partnership with MedImmune. He served as Director of Business Development at Millennium Pharmaceuticals, where he was responsible for negotiating drug discovery partnerships with large pharmaceutical companies. Dr. Cappel served as Director of Business Development at Cygnus Corporation, responsible for partnering activities in Europe and Japan. He has extensive expertise in forming strategic alliances with major pharmaceutical and biotechnology companies. He received his B.S. in Pharmacy and a Ph.D. in Pharmaceutics from J.W. Goethe University, Frankfurt, Germany, as well as an MBA from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.

Ms. Susan M. Kanaya has been Chief Financial & Administrative Officer, Executive Vice President and Secretary at Chemocentryx, Inc. since October 20, 2016 and February 2006 respectively. Ms. Kanaya served as the Chief Financial Officer and Senior Vice President of Finance at Chemocentryx, Inc. from January 2006 to October 20, 2016. Ms. Kanaya served as Senior Vice President, Finance of Kosan Biosciences Inc. from January 2002 to January 2006 and served as its Chief Financial Officer November 1999 to January 1,2006 and served as Principal Accounting Officer until January 2006. Ms. Kanaya served as Secretary of Kosan Biosciences from June 2001 to June 2004. From November 1999 to January 2002, she served as Vice President, Finance of Kosan Biosciences Inc., where she was responsible for all financial and accounting operations, investor and public relations, information technology and other corporate-related matters. Among her accomplishments at Kosan Ms. Kanaya was instrumental in securing more than $165 million in equity and debt financing, including an $80 million initial public offering. From 1994 to November 1999, she was employed by SUGEN, Inc., a publicly held biotechnology company that was acquired by Pharmacia in 1999, most recently serving as Vice President, Finance and Treasurer. Before joining SUGEN, she served as the Controller at 50/50 Micro Electronics, Inc., and at Power Up Software Corporation, a computer software company. She also served as Controller with high technology companies and as a Public Accountant with KPMG. Ms. Kanaya received a B.S. in business administration from the University of California, Berkeley.

Dr. Jan L. Hillson, M.D, has been Senior Vice President of Drug Development at ChemoCentryx, Inc. since November 2016. Dr. Hillson bringing two decades experience in academic rheumatology research, patient care and teaching and more than a decade directing strategy and operations related to clinical research and translational medicine. From 2013 to 2016, Dr. Hillson served as Vice President of Clinical and Translational Research at Momenta Pharmaceuticals; from 2007 to 2013 she served as Senior Director at ZymoGenetics/Bristol Myers Squibb, leading Clinical Research and Pharmacology for projects in immunology and immuno-virology. Prior to 2007, Dr. Hillson served in several positions, including Medical Director at Xcyte Therapies, Clinical Faculty at Harvard Medical School (Cambridge Health Alliance), Assistant Professor at University of Washington and Division Head at Virginia Mason Medical Center providing consultative and direct patient care, with a sub-specialty in uncommon autoimmune diseases, including vasculitis, systemic lupus, scleroderma and myositis. Dr. Hillson received her M.D. from Stanford School of Medicine, an M.S. from the California Institute of Technology and Scripps Institute of Oceanography and a B.S. from Michigan State University.

Dr. Rajinder Singh, Ph.D. has been Senior Vice President of Research at ChemoCentryx, Inc. since May 2016. Prior to joining ChemoCentryx, Dr. Singh held various management positions at Rigel Pharmaceuticals, Inc. (Rigel). Most recently and for the past ten years, he was Vice President, Chemistry at Rigel, where he oversaw the advancement of several drug candidates from discovery to clinical development, which included the filing of numerous Investigational New Drug applications in the areas of immunology and oncology. Prior to joining Rigel, he was a Lead Chemist at Chiron Corporation from 1994 to 1998. From 1992 to 1994, he was a Postdoctoral Fellow at Eli Lilly & Company. Dr. Singh received his Ph.D. degree in Organic Chemistry from the University of Oxford.

Jan Hillson serves as the Senior Vice President, Drug Development of ChemoCentryx. Jan started at ChemoCentryx in Dec of 2016. Jan currently resides in the Greater Seattle Area.

Rajinder Singh serves as the Sr. VP Research of ChemoCentryx. Rajinder started at ChemoCentryx in Jun of 2016. Rajinder currently resides in the San Francisco Bay Area.

May Kwan serves as the Vice President, Finance of ChemoCentryx. May started at ChemoCentryx in Mar of 2018. May currently resides in the San Francisco Bay Area.

Dalia Rayes serves as the Vice President, Marketing of ChemoCentryx. Dalia started at ChemoCentryx in May of 2018. Dalia currently resides in the San Francisco Bay Area.